1077 related articles for article (PubMed ID: 33422546)
1. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA
Adv Drug Deliv Rev; 2021 Mar; 170():113-141. PubMed ID: 33422546
[TBL] [Abstract][Full Text] [Related]
2. Recombinant protein vaccines, a proven approach against coronavirus pandemics.
Pollet J; Chen WH; Strych U
Adv Drug Deliv Rev; 2021 Mar; 170():71-82. PubMed ID: 33421475
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 evolution and vaccines: cause for concern?
Williams TC; Burgers WA
Lancet Respir Med; 2021 Apr; 9(4):333-335. PubMed ID: 33524316
[No Abstract] [Full Text] [Related]
4. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
[TBL] [Abstract][Full Text] [Related]
5. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
6. Non-viral COVID-19 vaccine delivery systems.
Park KS; Sun X; Aikins ME; Moon JJ
Adv Drug Deliv Rev; 2021 Feb; 169():137-151. PubMed ID: 33340620
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 mRNA vaccines.
Huang Q; Zeng J; Yan J
J Genet Genomics; 2021 Feb; 48(2):107-114. PubMed ID: 34006471
[TBL] [Abstract][Full Text] [Related]
8. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
Front Immunol; 2021; 12():658519. PubMed ID: 34276652
[TBL] [Abstract][Full Text] [Related]
9. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn.
Connors M; Graham BS; Lane HC; Fauci AS
Ann Intern Med; 2021 May; 174(5):687-690. PubMed ID: 33460347
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 vaccine candidates in rapid development.
Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines.
Zinatizadeh MR; Zarandi PK; Zinatizadeh M; Yousefi MH; Amani J; Rezaei N
Biomed Pharmacother; 2022 Feb; 146():112527. PubMed ID: 34906769
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 Vaccine: A comprehensive status report.
Kaur SP; Gupta V
Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
[TBL] [Abstract][Full Text] [Related]
14. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
Russell RL; Pelka P; Mark BL
Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
[TBL] [Abstract][Full Text] [Related]
15. A network analysis of COVID-19 mRNA vaccine patents.
Gaviria M; Kilic B
Nat Biotechnol; 2021 May; 39(5):546-548. PubMed ID: 33981074
[No Abstract] [Full Text] [Related]
16. SARS-CoV-2 vaccines - the biggest medical research project of the 21st century.
Kurup D; Schnell MJ
Curr Opin Virol; 2021 Aug; 49():52-57. PubMed ID: 34049261
[TBL] [Abstract][Full Text] [Related]
17. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
18. Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative.
Kyei-Barffour I; Addo SA; Aninagyei E; Ghartey-Kwansah G; Acheampong DO
Biomed Pharmacother; 2021 Dec; 144():112282. PubMed ID: 34624675
[TBL] [Abstract][Full Text] [Related]
19. Vaccines for COVID-19: The current state of play.
Koirala A; Joo YJ; Khatami A; Chiu C; Britton PN
Paediatr Respir Rev; 2020 Sep; 35():43-49. PubMed ID: 32653463
[TBL] [Abstract][Full Text] [Related]
20. A perspective on SARS-CoV-2 virus-like particles vaccines.
Gao X; Xia Y; Liu X; Xu Y; Lu P; Dong Z; Liu J; Liang G
Int Immunopharmacol; 2023 Feb; 115():109650. PubMed ID: 36649673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
